Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)

Trial Profile

Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Botulinum toxin A (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms Botulinum toxin-A versus tolterodine for idiopathic overactive bladder; OVERT
  • Most Recent Events

    • 04 Dec 2015 Accrual to date is 15% according to United Kingdom Clinical Research Network record
    • 12 Nov 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network record
    • 05 Oct 2015 Accrual to date is 6% according to United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top